US biotech Moderna strikes deal to develop mRNA drugs in China
莫德纳将生产专供中国市场的mRNA药物
Medicines produced by pharma group will be for domestic use only
美国生物科技公司莫德纳周三确认，已与中国有关部门达成协议，研究、开发和生产“不会出口（至中国以外地区）”的药物。
US drugmaker Moderna has struck a deal to make messenger RNA drugs for use in China, despite the tensions between Washington and Beijing.
尽管目前美中关系持续紧张，但美国制药企业莫德纳(Moderna)已达成协议，将生产专供中国使用的信使核糖核酸(mRNA)药物。
The biotech said on Wednesday that it had reached an agreement with authorities in Beijing to research, develop and manufacture drugs that would “not be exported”.
这家生物科技公司周三表示，它已与中国有关部门达成协议，将研究、开发和生产“不会出口（至中国以外地区）”的药物。
“Any medicines produced under this agreement will be exclusively for the Chinese people — who facemany ofthe same health challenges that affect other communities around the world,” the company said in a statement.
该公司在声明中表示：“根据该协议生产的任何药物都将专门提供给中国人——他们面临的许多健康挑战与世界其他地区面临的相同。”
